U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H10ClN3O3
Molecular Weight 315.711
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLONAZEPAM

SMILES

[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3Cl)C2=C1

InChI

InChIKey=DGBIGWXXNGSACT-UHFFFAOYSA-N
InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

HIDE SMILES / InChI

Description

Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Klonopin is the brand name for Clonazepam, an anxiolytic and anticonvulsant. The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacological options for the treatment of Tourette's disorder.
2001
Carbamazepine treatment of corticosteroid-induced mood disorder.
2001 Aug
Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients.
2001 Dec
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy.
2001 Dec
Roles for mitochondrial and reverse mode Na+/Ca2+ exchange and the plasmalemma Ca2+ ATPase in post-tetanic potentiation at crayfish neuromuscular junctions.
2001 Dec 15
Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.
2001 Mar-Apr
Stiff leg syndrome: case report.
2001 Nov
Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor.
2001 Nov
Selective, high-resolution fluorescence imaging of mitochondrial Ca2+ concentration.
2001 Nov
Determination of benzodiazepines in human hair by on-line high-performance liquid chromatography using a restricted access extraction column.
2001 Nov 15
Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant.
2002 Jan
Patents

Sample Use Guides

In Vivo Use Guide
Seizure Disorders: Adults: The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg. Clonazepam is available as a tablet or an orally disintegrating tablet (wafer). The tablets should be administered with water by swallowing the tablet whole. The orally disintegrating tablet should be administered as follows: After opening the pouch, peel back the foil on the blister. Do not push tablet through foil. Immediately upon opening the blister, using dry hands, remove the tablet and place it in the mouth. Tablet disintegration occurs rapidly in saliva so it can be easily swallowed with or without water.
Route of Administration: Oral
In Vitro Use Guide
Clonazepam (100 nM) increased inhibitory postsynaptic current (IPSC) decay time constants in rat thalamic nuclei-the reticular nucleus (nRt) (from 44.3 to 77.9 ms, P < 0.01) but not in the ventrobasal (VB) complex..
Name Type Language
CLONAZEPAM
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN   INN  
Official Name English
NSC-179913
Code English
CLONAZEPAM [JAN]
Common Name English
RIVOTRIL
Brand Name English
RO-5-4023
Code English
CLONAZEPAM [MART.]
Common Name English
RIVATRIL
Brand Name English
RO 5-4023
Code English
2H-1,4-BENZODIAZEPIN-2-ONE, 5-(2-CHLOROPHENYL)-1,3-DIHYDRO-7-NITRO-
Systematic Name English
CLONAZEPAM [ORANGE BOOK]
Common Name English
5-(O-CHLOROPHENYL)-1,3-DIHYDRO-7-NITRO-2H-1,4-BENZODIAZEPIN-2-ONE
Common Name English
CLONAZEPAM [MI]
Common Name English
KLONOPIN
Brand Name English
CLONAZEPAM [EP]
Common Name English
RO-54023
Code English
CLONAZEPAM [WHO-DD]
Common Name English
CLONAZEPAM [INN]
Common Name English
RAVOTRIL
Brand Name English
CLONAZEPAM [VANDF]
Common Name English
CLONAZEPAM [USP]
Common Name English
CLONAZEPAM CIV [USP-RS]
Common Name English
CLONAZEPAM [HSDB]
Common Name English
CLONAZEPAM CIV
USP-RS  
Common Name English
CLONAZEPAM [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175694
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
WHO-VATC QN03AE01
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
WHO-ATC N03AE01
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
NDF-RT N0000007542
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
DEA NO. 2737
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
LIVERTOX 224
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
Code System Code Type Description
PUBCHEM
2802
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY SWITZERF
WIKIPEDIA
CLONAZEPAM
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
RXCUI
2598
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY RxNorm
DRUG BANK
DB01068
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
CAS
1622-61-3
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
MESH
D002998
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
MERCK INDEX
M3649
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY Merck Index
LactMed
1622-61-3
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
ECHA (EC/EINECS)
216-596-2
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
EPA CompTox
1622-61-3
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
INN
2765
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
NCI_THESAURUS
C28935
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
EVMPD
SUB06728MIG
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
ChEMBL
CHEMBL452
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
HSDB
1622-61-3
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY
IUPHAR
6963
Created by admin on Tue Mar 06 10:25:18 UTC 2018 , Edited by admin on Tue Mar 06 10:25:18 UTC 2018
PRIMARY